<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935389</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0903</org_study_id>
    <nct_id>NCT00935389</nct_id>
  </id_info>
  <brief_title>Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria</brief_title>
  <official_title>Prospective Control Study of TW in the Treatment of LN Type V With Gross Proteinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the clinical effects and adverse reactions of
      tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with cyclophosphamide(CTX), to analyze the clinical effects and adverse reactions of
      tripterygium glycosides (TW) in LN-V patients with gross proteinuria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To analyze the clinical effects of tripterygium glycosides (TW) in LN-V patients with gross proteinuria.</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Lupus Nephritis</condition>
  <condition>Proteinuria</condition>
  <condition>CTX</condition>
  <arm_group>
    <arm_group_label>immunosuppressor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TW 30mg,q.d.*3 months and reduced into 20mg b.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tripterygium glycosides</intervention_name>
    <description>The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.</description>
    <arm_group_label>immunosuppressor</arm_group_label>
    <other_name>TW</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. SLE patients aging 18-60 years, all of whom comply to the ISN/RPS classification.

          2. Urine proteinâ‰¥3.0g/24h, Alb&lt;30g/L and Scr&lt;1.5mg/dL.

          3. All cases are type IV, confirmed by renal biopsy.

          4. All patients sign the informed consent and be willing to follow-up on time

        Exclusion Criteria:

          1. Accepted drug therapy, such as CTX MMF CsA FK506 or TW more than 2 weeks in the latest
             3 months.

          2. Scr level above 1.5mg/dL, lasts more than 3 months.

          3. Heart, lung or central nervous systems involved or combined with severe infection.

          4. With liver function abnormal, ALT or AST being two times above the normal.

          5. Pregnant women or patients still in lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hu Weixin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jinling Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Nephrology,Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nanjing University School of Medicine</name_title>
    <organization>Nanjing University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

